$IRD

Opus Genetics, Inc.

No enriched coverage for $IRD in the last 7 days.

No SEC Form 4 filings for $IRD in the last 30 days.

Med

This Live Nation Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Benzinga reports on five new analyst initiations for Monday, March 30, 2026. Live Nation Entertainment (LYV) received a Market Outperform rating from Citizens, along with FuboTV (FUBO). Other initiations include TSS Inc (TSSI) with a Buy rating from Needham, Netflix Inc (NFLX) with a Market Perform from Citizens, and Opus Genetics Inc (IRD) with an Overweight rating from Cantor Fitzgerald.

Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst

Viatris Inc. (VTRS) and Opus Genetics, Inc. (IRD) announced the completion of a Phase 3 clinical trial for Nyxol (0.75% phentolamine ophthalmic solution), an eye drop designed to improve low-light and night vision for patients who have visual disturbances after refractive surgery. The trial's completion reduces development risk, but market reaction for involved companies will likely remain muted until the efficacy and safety data are publicly released. Positive results could create a new revenue stream for Viatris in specialty eye care and significantly impact Opus Genetics' valuation.